Press release
Psoriasis Market: Epidemiology, Therapies, and Companies, DelveInsight | Featuring Amgen, Janssen, AbbVie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc
Psoriasis Market
Psoriasis companies are LEO Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, Genentech, and others.
Emerging therapies for psoriasis, including Imsidolimab, TAK-279, Sonelokimab, and others, are anticipated to drive growth in the psoriasis market in the coming years.
DelveInsight has released a new report titled "Psoriasis - Market Insights, Epidemiology, and Market Forecast-2034", providing a comprehensive analysis of psoriasis, its historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover more about the psoriasis disease, diagnosis, and treatment options @ https://www.delveinsight.com/report-store/psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the Psoriasis Market Report:
*
Psoriasis impacts roughly 1% to 8% of the global population, with about one-third of cases starting in childhood. In the United States, an estimated 8 million people were diagnosed with psoriasis in 2023, with plaque psoriasis being the most prevalent form, affecting approximately 68% of patients, followed by inverse psoriasis. Additionally, around 28% of U.S. psoriasis patients were estimated to have genital psoriasis in 2023, while scalp psoriasis also remains a common subtype.
*
In October 2023, the FDA approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis eligible for systemic therapy or phototherapy. BIMZELX is notable as the first and only treatment approved to target both IL-17A and IL-17F.
*
Key companies developing psoriasis therapies include Amgen, Janssen, AbbVie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, Genentech, and others, all working to enhance the psoriasis treatment landscape.
*
Promising pipeline therapies include Imsidolimab, TAK-279, Sonelokimab, and others.
Psoriasis Overview
Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by the formation of papules and plaques. It occurs due to an overactive immune response, which causes inflammation and speeds up skin cell turnover.
Plaque psoriasis is the most common type, while less frequent forms include inverse, pustular, guttate, and erythrodermic psoriasis.
Although a cure is not yet available, several effective treatments exist. Topical therapies are the mainstay for mild to moderate cases, often using corticosteroids, vitamin D analogs, and occasionally phototherapy. More severe cases generally require systemic therapies.
Psoriasis Market Outlook
Psoriasis is a chronic, relapsing skin disorder that often necessitates long-term management. Treatment selection depends on factors such as disease severity, coexisting conditions, and healthcare access. Patients are typically categorized as having mild or moderate-to-severe psoriasis, based on lesion intensity, the percentage of body surface affected, and impact on quality of life.
The current therapeutic landscape is primarily led by TNF inhibitors, interleukin inhibitors, and vitamin D analogs. Market expansion is driven by the increasing adoption of biologics, a shift toward personalized medicine, and wider accessibility of topical treatments. Recent approvals of oral TYK2 inhibitors and nonsteroidal topical therapies have further broadened treatment options, enhancing market competition.
BIMZELX (bimekizumab-bkzx) is a monoclonal antibody developed to treat autoimmune conditions such as moderate to severe plaque psoriasis. It works by dual inhibition of interleukin-17A and interleukin-17F, key cytokines in the inflammatory cascade. In October 2023, the U.S. FDA approved BIMZELX for adults suitable for systemic therapy or phototherapy.
Discover how the psoriasis market is growing in the coming years @ https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Psoriasis Therapies and Key Companies
*
Imsidolimab: AnaptysBio
*
TAK-279: Nimbus Lakshmi/Takeda
*
Sonelokimab: MoonLake Immunotherapeutics
To know more about the emerging therapies and companies that will drive the psoriasis treatment market, click: https://www.delveinsight.com/report-store/psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Scope of the Psoriasis Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Psoriasis Companies: Amgen, Janssen, Abbvie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, Genentech, and others
*
Key Psoriasis Therapies: Imsidolimab, TAK-279, Sonelokimab, and others
*
Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
*
Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Psoriasis Unmet Needs, KOL's views, Analyst's views, Psoriasis Market Access and Reimbursement
Key benefits of the Psoriasis market report:
*
The Psoriasis market report covers a descriptive overview and comprehensive insight of the Psoriasis Epidemiology and Psoriasis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan)..)
*
The Psoriasis market report provides insights intoon the current and emerging therapies.
*
The Psoriasis market report provides a global historical and forecasted market covering drug outreach in 7MM.
*
The Psoriasis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psoriasis market.
Got queries? Click here to know more about the Psoriasis Market Landscape [https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Psoriasis Patient Share (%) Overview at a Glance
5. Psoriasis Market Overview at a Glance
6. Psoriasis Disease Background and Overview
7. Psoriasis Epidemiology and Patient Population
8. Country-Specific Patient Population of Psoriasis
9. Psoriasis Current Treatment and Medical Practices
10. Unmet Needs
11. Psoriasis Emerging Therapies
12. Psoriasis Market Outlook
13. Country-Wise Psoriasis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Psoriasis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Psoriasis Market Outlook 2034 [https://www.delveinsight.com/report-store/psoriasis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Related Reports:
Psoriasis Pipeline Insights, DelveInsight
"Psoriasis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Psoriasis market. A detailed picture of the Psoriasis pipeline landscape is provided, which includes the disease overview and Psoriasis treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriasis-market-epidemiology-therapies-and-companies-delveinsight-featuring-amgen-janssen-abbvie-novartis-astrazeneca-bausch-health-eli-lilly-sun-pharmaceutical-janssen-biotech-ucb-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Market: Epidemiology, Therapies, and Companies, DelveInsight | Featuring Amgen, Janssen, AbbVie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc here
News-ID: 4178163 • Views: …
More Releases from ABNewswire
Zorendi Explores a New Automotive Era Where Cars Become Signals Not Machines
Dubai is one of those rare places where cars talk before people do. They say things about pressure, dreams, money, insecurity, success, even loneliness. You can read a whole backstory in the first thirty seconds at a traffic light. But most of those decisions don't start on the road. They start online, scrolling, comparing, imagining, hunting through pages of listings and thinking you're just doing "research".
And somewhere between curiosity and…
The E-Book Oasis LLC Delivers One-Stop Shopping Experience for Digital Content a …
The E-Book Oasis LLC provides American consumers with a unified marketplace combining e-books, podcasts, apparel, and gifts. The company's integrated platform serves both individual readers and business customers seeking literary content and merchandise solutions.
In an era where digital content consumption continues to rise and niche retail experiences attract loyal followings, The E-Book Oasis LLC has carved out a distinctive position in the marketplace. The company operates as a comprehensive retail…
Functional Food Market Size to Reach USD 211.7 Billion by 2030, Driven by Rising …
Mordor Intelligence has published a new report on theFunctional Food Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Functional Food Market Outlook
The Functional Food Market [https://www.mordorintelligence.com/industry-reports/global-functional-food-market?utm_source=abnewswire] continues to gain traction globally as consumers increasingly prioritize health and wellness alongside taste and convenience. Functional foods are enriched with vitamins, minerals, probiotics, and bioactive compounds that provide benefits beyond basic nutrition. In 2025, the global market size reached USD…
UNFINISHED SONATA: An Immersive theater Where Music, Dance, and Wine Unfold an U …
On December 20 and 21, 2025, Blanc Gallery in New York City hosted UNFINISHED SONATA, a four-performance immersive theater experience curated by the international art and design incubation platform NotYetArt (NYA). More than one hundred audience members attended the sold-out performances, moving freely through a spatial narrative of live music, dance, handwritten letters, candlelight, and wine.
Audiences were not spectators but witnesses, encountering the story at intimate range through passing glances,…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
